Compare AEVA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | STTK |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 119.0M |
| IPO Year | N/A | 2020 |
| Metric | AEVA | STTK |
|---|---|---|
| Price | $13.14 | $3.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $26.50 | $4.00 |
| AVG Volume (30 Days) | ★ 2.0M | 424.7K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,154,000.00 | $1,000,000.00 |
| Revenue This Year | $87.44 | N/A |
| Revenue Next Year | $70.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 89.90 | N/A |
| 52 Week Low | $2.52 | $0.69 |
| 52 Week High | $38.80 | $3.38 |
| Indicator | AEVA | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 72.67 |
| Support Level | $12.83 | $2.82 |
| Resistance Level | $15.73 | $3.29 |
| Average True Range (ATR) | 1.24 | 0.23 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 6.67 | 94.64 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.